- Home
- AENT vs XGN Comparison
AENT vs XGN Comparison
Compare AENT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- XGN
- Stock Information
- Founded
- AENT 1990
- XGN 2002
- Country
- AENT United States
- XGN United States
- Employees
- AENT N/A
- XGN N/A
- Industry
- AENT Durable Goods
- XGN Medical Specialities
- Sector
- AENT Consumer Discretionary
- XGN Health Care
- Exchange
- AENT Nasdaq
- XGN Nasdaq
- Market Cap
- AENT 141.2M
- XGN 138.3M
- IPO Year
- AENT N/A
- XGN 2019
- Fundamental
- Price
- AENT $3.54
- XGN $7.17
- Analyst Decision
- AENT
- XGN Strong Buy
- Analyst Count
- AENT 0
- XGN 2
- Target Price
- AENT N/A
- XGN $7.50
- AVG Volume (30 Days)
- AENT 28.4K
- XGN 220.5K
- Earning Date
- AENT 05-15-2025
- XGN 08-04-2025
- Dividend Yield
- AENT N/A
- XGN N/A
- EPS Growth
- AENT N/A
- XGN N/A
- EPS
- AENT 0.23
- XGN N/A
- Revenue
- AENT $1,072,641,000.00
- XGN $56,724,000.00
- Revenue This Year
- AENT $4.77
- XGN $19.39
- Revenue Next Year
- AENT N/A
- XGN $13.27
- P/E Ratio
- AENT $15.66
- XGN N/A
- Revenue Growth
- AENT N/A
- XGN 1.78
- 52 Week Low
- AENT $1.10
- XGN $1.71
- 52 Week High
- AENT $11.57
- XGN $7.56
- Technical
- Relative Strength Index (RSI)
- AENT 63.81
- XGN 63.16
- Support Level
- AENT $3.19
- XGN $6.51
- Resistance Level
- AENT $3.68
- XGN $7.50
- Average True Range (ATR)
- AENT 0.32
- XGN 0.54
- MACD
- AENT 0.11
- XGN 0.02
- Stochastic Oscillator
- AENT 76.74
- XGN 80.10
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.